Pittsburgh, Pennsylvania and Toronto, Ontario — October 14, 2025 — Leads & Copy — Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) has announced a non-brokered private placement to raise gross proceeds of not less than US$10,000,000. The placement will consist of common shares priced at not less than US$2.50 per share, with an expected closing in the fourth quarter of 2025. Net proceeds will be used for general working capital purposes.
STX Partners, LLC, Sharp’s largest shareholder, has committed to purchase not less than 1,200,000 common shares at US$2.50 per share, representing approximately US$3,000,000 in gross proceeds, contingent upon Sharp raising not less than US$7,000,000 from other investors and the Offering closing by December 15, 2025. Other insiders will also participate in the Offering.
John Hathaway, managing partner of STX, expressed excitement to add to their investment position and praised the scientific progress, including the Gaucher development candidate.
Sharp’s CEO, Scott Sneddon, PhD, JD, is pleased to have STX’s significant commitment, which will allow Sharp to generate key human efficacy data in Phase I trials for ‘901, an oral, CNS penetrant treatment for all forms of Gaucher and other lysosomal storage disorders.
All securities issued will be subject to a four-month hold period and TSX Venture Exchange approval. The securities have not been registered under the United States Securities Act of 1933 and may not be offered or sold in the United States without registration or an applicable exemption.
Sharp Therapeutics is a preclinical-stage company developing first-choice small-molecule therapeutics for genetic diseases, utilizing a discovery platform that combines novel high throughput screening technologies with compound libraries computationally optimized.
Contact: Scott Sneddon, PhD, JD, CEO/CSO, Email: scott@sharptx.com
Source: Sharp Therapeutics Corp.
